Breast cancer survival trends in different stages and age groups - a population-based study 1989-2013.


Journal

Acta oncologica (Stockholm, Sweden)
ISSN: 1651-226X
Titre abrégé: Acta Oncol
Pays: England
ID NLM: 8709065

Informations de publication

Date de publication:
Jan 2019
Historique:
pubmed: 5 12 2018
medline: 14 6 2019
entrez: 5 12 2018
Statut: ppublish

Résumé

During the recent decades, breast cancer survival has gradually improved but there is limited knowledge on the improvement in population-based studies of patients diagnosed with different stages of the disease and in different age groups. In two Swedish health care regions a total of 42,220 female breast cancer patients below 90 years of age were diagnosed between 1989 and 2013. They were treated and followed according to national and regional guidelines and formed a population-based cohort. Using patients diagnosed in 1989-1993 as a reference to the relative risk, 5-year mortality decreased with 49% for patients diagnosed at the end of the observation period (CI 95% 45-58). The mortality tended to decrease for patients with all stages of breast cancer and test for trend resulted in a statistically significant improvement over time in 5-year relative survival in stage III and IV and in 10-year survival in stage I and III. For each operable stage of disease, patients aged below 40 years or more than 70 years when diagnosed tended to have less favorable survival than patients diagnosed between 40-69 years of age. Test for trend resulted in statistically significant improvements over time for patients diagnosed at ages below 40, 40-54 and 54-69, but less marked improvements for patients older than 70 when diagnosed. During the period 1989-2013 the relative risk of 5-year mortality decreased with 49%. Improvements were seen in all age groups but were unevenly distributed between stages and age groups pointing to the need for further improvements for younger and elderly patients.

Sections du résumé

BACKGROUND BACKGROUND
During the recent decades, breast cancer survival has gradually improved but there is limited knowledge on the improvement in population-based studies of patients diagnosed with different stages of the disease and in different age groups.
PATIENTS AND METHODS METHODS
In two Swedish health care regions a total of 42,220 female breast cancer patients below 90 years of age were diagnosed between 1989 and 2013. They were treated and followed according to national and regional guidelines and formed a population-based cohort.
RESULTS RESULTS
Using patients diagnosed in 1989-1993 as a reference to the relative risk, 5-year mortality decreased with 49% for patients diagnosed at the end of the observation period (CI 95% 45-58). The mortality tended to decrease for patients with all stages of breast cancer and test for trend resulted in a statistically significant improvement over time in 5-year relative survival in stage III and IV and in 10-year survival in stage I and III. For each operable stage of disease, patients aged below 40 years or more than 70 years when diagnosed tended to have less favorable survival than patients diagnosed between 40-69 years of age. Test for trend resulted in statistically significant improvements over time for patients diagnosed at ages below 40, 40-54 and 54-69, but less marked improvements for patients older than 70 when diagnosed.
CONCLUSIONS CONCLUSIONS
During the period 1989-2013 the relative risk of 5-year mortality decreased with 49%. Improvements were seen in all age groups but were unevenly distributed between stages and age groups pointing to the need for further improvements for younger and elderly patients.

Identifiants

pubmed: 30513223
doi: 10.1080/0284186X.2018.1532601
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

45-51

Auteurs

Anna E Nordenskjöld (AE)

a Department of Medicine and Oncology , Southern Älvsborg Hospital , Borås , Sweden.

Helena Fohlin (H)

b Regional Cancer Center Southeast Sweden, and Department of Clinical and Experimental Medicine , Linköping University , Linköping , Sweden.

Lars G Arnesson (LG)

c Department of Surgery , University Hospital , Linköping , Sweden.

Zakaria Einbeigi (Z)

d Department of Oncology , Institute of Clinical Sciences at Sahlgrenska Academy, University of Gothenburg Sahlgrenska University Hospital , Gothenburg , Sweden.

Erik Holmberg (E)

e Regional Cancer Center , Sahlgrenska University Hospital , Gothenburg , Sweden.

Per Albertsson (P)

d Department of Oncology , Institute of Clinical Sciences at Sahlgrenska Academy, University of Gothenburg Sahlgrenska University Hospital , Gothenburg , Sweden.

Per Karlsson (P)

d Department of Oncology , Institute of Clinical Sciences at Sahlgrenska Academy, University of Gothenburg Sahlgrenska University Hospital , Gothenburg , Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH